JANSSEN
11.3.2019 13:51:04 CET | Business Wire | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3 UNIFI maintenance study. The data showed that a significantly greater proportion of adults with moderate to severe ulcerative colitis (UC) receiving ustekinumab subcutaneous (SC) maintenance therapy were in clinical remission* at Week 44, compared to patients receiving placebo – the study’s primary endpoint.1 Patients receiving ustekinumab SC maintenance therapy had a clinical response 8 weeks after receiving a single intravenous (IV) dose of ustekinumab.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190311005469/en/
These data were presented as part of a plenary session (Abstract OP37) at the 14th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Copenhagen, Denmark. At the Congress, Janssen also shared a digital oral presentation with additional data from the UNIFI induction study evaluating the effects of ustekinumab on histo-endoscopic mucosal healing (HEMH), a novel, pre-specified endpoint in this programme.
Results from the maintenance phase of the Phase 3 study demonstrated that 44 percent (90 mg every 8 weeks [q8w]) and 38 percent (90 mg every 12 weeks [q12w]) of patients with moderate to severe UC receiving ustekinumab SC injections achieved clinical remission, as defined by the Mayo score, at week 44 (52 weeks after IV induction) compared to 24 percent of patients who received placebo (p<0.001 and p=0.002, respectively).1 These data were included in submissions to the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) seeking approval of ustekinumab as a treatment for UC.
“Ulcerative colitis is a disruptive, lifelong and potentially debilitating inflammatory bowel disease; however, it is a condition where remission is possible,” said lead study investigator William Sandborn, MD, Chief, Division of Gastroenterology and Professor of Medicine, University of California, San Diego. “The data suggest the potential of ustekinumab as an effective therapy for helping people living with ulcerative colitis achieve remission, as well as providing other meaningful outcomes, including clinical response, histo-endoscopic improvement and corticosteroid-free remission.”
Major secondary endpoints, including maintenance of clinical response, endoscopic improvement, corticosteroid-free remission and maintenance of clinical remission from baseline, were also achieved in greater proportions of patients receiving ustekinumab q8w and q12w injections versus patients receiving placebo. At week 44:
- 71 percent of patients receiving ustekinumab q8w and 68 percent of patients receiving ustekinumab q12w maintained clinical response, compared with 44 percent of patients receiving placebo (both p<0.001).1 Clinical response was defined as a decrease from baseline in the Mayo score by ≥30 percent and ≥3 points, with a rectal bleeding sub-score of 0 or 1 or a decrease in the rectal bleeding sub-score ≥1
- 51 percent of patients receiving ustekinumab q8w and 44 percent of patients receiving ustekinumab q12w achieved endoscopic improvement, compared with 29 percent of patients receiving placebo (p<0.001 and p=0.002, respectively).1 Endoscopic improvement was defined as a Mayo endoscopy sub-score of 0 (normal mucosa or inactive disease) or 1 (mild disease activity)
- 42 percent of patients receiving ustekinumab q8w and 38 percent of patients receiving ustekinumab q12w were in clinical remission and were corticosteroid-free, compared with 23 percent of patients receiving placebo (p<0.001 and p=0.002, respectively).1 The global remission definition was a Mayo score ≤2 points, with no individual sub-score >1
Through to week 44, the proportions of patients with adverse events (AEs), serious AEs, infections and serious infections in the ustekinumab groups were generally comparable to the placebo group. The proportions of patients who discontinued the study agent were lower with ustekinumab q8w and q12w versus placebo. Among the primary population in the maintenance study, no deaths occurred. Two malignancies other than non-melanoma skin cancer (NMSC) (one colon cancer, q8w; one papillary renal cell carcinoma, q12w) were reported. One patient reported NMSC (two squamous cell carcinoma events, q12w).1 Overall, the safety for ustekinumab in UC patients was consistent with the known safety profile of ustekinumab in Crohn’s disease (CD).2
“The UNIFI maintenance data further build the case for ustekinumab as a potential new treatment option for ulcerative colitis and illustrate our ongoing commitment to researching and developing meaningful therapies for people living with inflammatory bowel diseases,” said Scott E. Plevy, M.D., Gastroenterology Disease Area and IL-23 Pathway Leader, Janssen Research & Development, LLC† . “Furthermore, we are proud that UNIFI is the first Phase 3 study to report a combined histo-endoscopic endpoint in patients with ulcerative colitis.”
In the abstract (DOP71) presenting the induction study colonic mucosal healing results, patients achieved higher rates of endoscopic improvement, histologic improvement and the combined endpoint of histo-endoscopic mucosal healing (HEMH), versus placebo, 8 weeks after receiving a single IV induction dose of ustekinumab.3 Histo-endoscopic mucosal healing assesses how the colon is responding both histologically and endoscopically to therapy and both have been associated with improved long-term clinical outcomes, such as reduced risk of relapse and need for surgery/hospitalisation, and reduced risk of developing cancer.4
#ENDS#
About the UNIFI trial
UNIFI is
a Phase 3 protocol, designed to evaluate the safety and efficacy of
ustekinumab induction and maintenance dosing for the treatment of
moderate to severe UC in adults who demonstrated an inadequate response
to, or were unable to tolerate, conventional (i.e., corticosteroids,
immunomodulators) or biologic (i.e., one or more TNF blockers and/or
vedolizumab) therapies. Both the induction and maintenance studies are
randomised, double-blind, placebo-controlled, parallel group,
multicentre studies. The induction study was conducted over a duration
of at least 8 weeks for each participant. Participants achieving
clinical response in the induction study were eligible for the
maintenance study. The maintenance study was 44 weeks in duration. The
primary endpoint of the induction study was clinical remission at week
8, and the primary endpoint for the maintenance study was clinical
remission at week 44 among responders to a single IV ustekinumab
infusion. After completion of the maintenance study, a long-term
extension study will follow eligible participants for an additional
three years.
About ulcerative colitis
Ulcerative
colitis affects up to 2.6 million people in Europe.5
It is a
chronic disease of the large intestine, also known as the colon, in
which the lining of the colon becomes inflamed and develops tiny open
sores, or ulcers, that produce pus and mucous. Ulcerative colitis is the
result of an abnormal response by the body's immune system. Symptoms
vary, but may include loose and more urgent bowel movements, persistent
diarrhoea, abdominal pain, bloody stool, loss of appetite, weight loss
and fatigue.6
About STELARA
®
(ustekinumab)
2
In the European Union,
ustekinumab is approved for the treatment of moderate to severe plaque
psoriasis in adults who failed to respond to, or who have a
contraindication to, or are intolerant to other systemic therapies
including ciclosporin, methotrexate (MTX) or psoralen plus ultraviolet
A, and is also indicated for the treatment of moderate to severe plaque
psoriasis in adolescent patients aged 12 years and older who are
inadequately controlled by or are intolerant to other systemic therapies
or phototherapies. In addition, ustekinumab is approved alone or in
combination with MTX for the treatment of active psoriatic arthritis in
adult patients when the response to previous non-biological
disease-modifying antirheumatic drug therapy has been inadequate. In
November 2016, the European Commission approved ustekinumab for the
treatment of adult patients with moderate to severe CD who have had an
inadequate response with, lost response to, or were intolerant to either
conventional therapy or a TNF-alpha antagonist or have medical
contraindications to such therapies.
The Janssen Pharmaceutical Companies of Johnson & Johnson maintain exclusive worldwide marketing rights to ustekinumab. In December 2018, a Group Type II Variation Application to the EMA was submitted, which seeks approval of ustekinumab for the treatment of adults with moderate to severe UC.
About the Janssen Pharmaceutical Companies of
Johnson & Johnson
At Janssen, we’re creating a
future where disease is a thing of the past. We’re the Pharmaceutical
Companies of Johnson & Johnson, working tirelessly to make that future a
reality for patients everywhere by fighting sickness with science,
improving access with ingenuity, and healing hopelessness with heart. We
focus on areas of medicine where we can make the biggest difference:
Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines,
Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com/EMEA . Follow us on Twitter: @JanssenEMEA. Janssen Research & Development, LLC is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
# # #
References
1. W.J Sandborn, B.E Sands, R. Panaccione, et
al.
Efficacy and safety of ustekinumab as maintenance therapy in
ulcerative colitis: Week 44 resultus from UNIFI [Abstract OP37].
Presented at European Crohn’s and Colitis Organisation (ECCO 2019) 6-9
March, 2019; Copenhagen, Denmark.
2. European Medicines Agency.
(2016) Ustekinumab Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf
.
Accessed March 2019.
3. K. Li, J.R Friedman, C Marano, et al.
Effects of ustekinumab induction therapy on endoscopic and histological
healing in the UNIFI Phase 3 study in ulcerative colitis [Abstract
DOP71]. Presented at European Crohn’s and Colitis Organisation (ECCO
2019) 6-9 March, 2019; Copenhagen, Denmark.
4. GI Health
Foundation. What is Mucosal Healing? Available at: http://www.gihealthfoundation.org/GI_news_and_library/library/ppts/IBD/WhatisMucosalHealing.pdf
.
Accessed March 2019.
5. Ng SC, Shi HY, Underwood FE, et al
.
Worldwide incidence and prevalence of inflammatory bowel disease in the
21st
century: a systematic review of population-based
studies. Lancet
2017;390:2769-78.
6. Crohn’s & Colitis
Foundation. What is Ulcerative Colitis? Available at: http://www.crohnscolitisfoundation.org/what-are-crohns-and-colitis/what-is-ulcerative-colitis/
.
Accessed March 2019.
*Remission was defined as a Mayo score ≤2 points, with no individual sub-score >1. The Mayo score is designed to measure the severity of UC, giving a score from 0–12 points; a higher score indicates more severe disease activity
† Limited Liability Company
View source version on businesswire.com: https://www.businesswire.com/news/home/20190311005469/en/
Contact:
Media Contact: Emily Bone Phone: +44 787-639-4360 ebone1@its.jnj.com Investor Relations: Christopher DelOrefice Phone: +1 732-524-2955 Lesley Fishman Phone: +1 732-524-3922
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SatSure Raises Series B to Scale Its Full-Stack Earth Intelligence Platform for Global Markets20.11.2026 11:05:00 CET | Press release
India’s sovereign space-technology fund leads the first close of the ongoing INR 200 crore (c. USD 21 million) round SatSure, a global Earth intelligence company headquartered in India, today announced the first close of its ongoing INR 200 crore (c. USD 21 million) Series B round. The round is led by a INR 60 crore (c. USD 6.4 million) investment from the Antariksh Venture Capital Fund (AVCF), India’s sovereign space-technology fund, anchored by the national space regulator IN-SPACe and managed by SIDBI Venture Capital Limited. The investment marks AVCF’s first deployment into the downstream data and AI layer of India’s space economy, extending the fund beyond upstream launch and satellite hardware into commercial space-data infrastructure capable of serving global enterprise and sovereign markets. The round comprises INR 165 crore (c. USD 17.6 million) in equity, INR 25 crore (c. USD 2.7 million) in venture debt and INR 10 crore (c. USD 1.1 million) in secondary transactions, closing
Al Shera’a, DEWA’s Headquarters, Wins First Place in the YeS Honor Awards at the COP31 International Sustainable Buildings Competition20.11.2026 10:16:00 CET | Press release
In a new achievement that underscores Dubai’s pioneering position in smart and sustainable buildings, Al Shera’a, the headquarters of Dubai Electricity and Water Authority (DEWA), has won the first place in the YeS Honor Award–Sustainable Design category, in the COP31 International Sustainable Buildings Competition. The award was launched by the COP31 Presidency with the support of the Global Alliance for Buildings and Construction, hosted by the United Nations Environment Programme, during COP31 in Antalya, Türkiye. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118255551/en/ HE Saeed Mohammed Al Tayer, MD&CEO of DEWA, received the award in the presence of HE Amna bint Abdullah Al Dahak, UAE Minister of Climate Change and Environment, from HE Hasan Suver, Deputy Minister of Environment, Urbanisation and Climate Change of the Republic of Türkiye, representing the COP31 Presidency. The competition attracted more than 1,000
teamLab Biovortex Kyoto to Open 'Teahouse in a Sea of Light' for Savoring Tea. On View from Friday, November 20. Artworks Including Tea in Spontaneous Order on View20.11.2026 07:00:00 CET | Press release
teamLab Biovortex Kyoto opens ‘Teahouse in a Sea of Light’ on Friday, November 20, 2026, where visitors can savor tea within the Sea of Solidified Light. Artworks exhibited in the teahouse, including Tea in Spontaneous Order, are now unveiled. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117922442/en/ Aged Coffee Tonic, Tea in Spontaneous Order, 2021- ©︎ teamLab *Shot in real space. No AI or CGI. *No Artificial Colors Teahouse in a Sea of Light A space for savoring tea within a sea of light. When a cup of tea is made, the artwork is born. The tea interacts with nearby tea and the sea of light, creating a time structure throughout the entire space of the artwork. Visitors drink part of this formed order itself. Coinciding with the opening of ‘Teahouse in a Sea of Light,’ Pocket Garden of Eternal Existence is newly unveiled at the museum's entrance gate. teamLab Biovortex Kyoto teamLab Biovortex Kyoto is teamLab's largest
OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac
ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release
Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
